Figure 2.

Comparison of the efficacies of proscillaridin A and osimertinib in NSCLC cell lines with wild-type EGFR and EGFR mutations. Lung cancer A549 (A), H1975 (B), PC9 (C), and PC9IR (D) cell lines were treated with 100 nM osimertinib and 16 nM proscillaridin A at the indicated time points. Cell viability was measured by the PrestoBlue assay, and the results are presented as percentages of the vehicle control (0 hr, 0.1% DMSO). Each experiment was independently performed in triplicate. The statistical analysis showed *P < 0.05 compared with the vehicle control.